DISCOVERY& DEVELOPMENT US 2025

October 2 - 3, 2025 | San Diego, CA

Conference Brochure

Equipping biopharma innovators with critical intelligence and partners needed to discover, develop and deliver first-in-class drugs rapidly



8 Content Tracks Across Two Days



200+
Pre-Arranged
Meetings



35+ Partners



1,000+ Attendees

Composed of 3 Focus Areas





Automation & Robotics



Formulation & Delivery

Meet Your KEYNOTE SPEAKERS



DAY ONE | 09:15 💥

STEVE TURNER

Chief Executive Officer,
Pangio Biosystems &
Former Founding Chief
Executive Officer, PacBio

DAY TWO | 09:00 %

RAY DESHAIES

Former Senior Vice President of Global Research, Amgen



Book Now! Complimentary Industry, Academic or Investor Guest Passes Available

Register 💥

Sponsor



Co-located with Biologics US 2025 > More Information



Robotics.

Welcome to Discovery & Development US 2025 - where we unify 3 stand-out focus areas under one roof – Drug Discovery, Formulation & Delivery and Automation &

Join us for two days of high-level discussion & tailored content, spotlighting novel modalities & emerging computational tools to foster innovation. Our Drug Discovery program highlights the latest breakthroughs in target identification & validation, medicinal & Alguided computational chemistry & hit identification & screening. Join our exclusive track shining a light on degraders & molecular glues where you'll hear case studies on the current technology & platforms for their discovery & design.

Our featured automation & robotics sessions features all things AI & data-powered, from streamlining lab workflows with automation and FAIR data management & digital transformation to implementing robotics within labs to improve productivity & efficiency.

Finally, join our Formulation & Delivery program to learn about the latest advancements in the formulation of large and small moleculebased drugs, developments in RNA, peptide and oligonucleotide design; and explore the innovations in the delivery of complex and challenging

therapeutics.

This year, Discovery & Development US goes even further - co-located with Biologics US 2025, we offer 1000+ attendees the unique opportunity to engage across both communities and forging the path to the next generation of therapies that will transform lives and reshape the future of healthcare.

Charlotte Catley

Sponsorship Director, Oxford Global



& Insights

Sign up for our monthly newsletter to keep up with all things Discovery



BROCHURE CONTENTS

Welcome

Benefits of **Attending**

Sponsors

Special Event Features

Agenda at a Glance

Featured Speakers: Discovery

Featured Speakers: Formulation

All Speakers

Full **Programme:** Day One

Full **Programme:** Day Two

Venue Information

Book Now

X @OGConferences

WHAT'S NEW

Benefits Of Attending



Stay ahead of the curve: uncover how novel modalities like PROTACs, molecular glues, bispecific antibodies and beyond are reshaping the innovation landscape.



The latest in computational R&D: explore how AI-guided chemistry, advanced modeling and predictive tools are accelerating decision-making from discovery to human dose prediction.



Benchmark your lab against industry leaders: discover how automation & robotics can improve productivity for your workflows & exponentially decrease development time.



The use of Al – is it hype or is it justified? Make your decision by hearing from the experts using Al, data & digital transformation to drive drug discovery!



Discover the formulation breakthroughs redefining what's possible: from lipid and polymeric nanoparticles to automation technology and high-dosage therapies.



Keep your finger on the pulse of next-gen drug delivery:

hear how innovators are advancing RNA therapeutics, long-acting injectables, nanoparticle carriers, implants and inhalation approaches.

DON'T MISS THESE

Interactive Features

16:15 | Day 1
Panel Discussion:

The Status of AI/ML in Drug
Discovery: Where Are We and Where
Are We Going?

08:30 | Day 2

Roundtable Discussion:

IP Considerations in Early Discovery

12:10 | Day 2
Panel Discussion:

& Development

Sustainability Impact of Different Drug Delivery Methods

16:15 | Day 1
Industry Workshop:

The Changing Landscape of RNA
Design & Delivery

08:30 | Day 2
Roundtable Discussion:

From Drug Product Development to Overcoming Regulatory Hurdles

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Special Event Features

Agenda at a Glance

Featured
Speakers:
Discovery

Featured
Speakers:
Formulation

All Speakers

Full
Programme:
Day One

Full
Programme:
Day Two

Venue Information

Book Now



At Oxford Global, our mission is to curate personalised experiences that foster community and inspire innovation.

We believe in the power of networking, connection, and knowledge to deliver quality products and services that exceed expectations. Partnering with Oxford Global means having a dedicated team committed to helping you achieve your goals and navigating the industry's ever-changing landscape.

Arrange 1-1 Meetings

Benefit from guaranteed one-to-one face time with your key prospects, with detailed pre-meeting information provided to enable effective and productive conversations.

Speaking Opportunities

Showcase your company's recent work to a relevant and highly engaged audience.

✓ Host Panel & Roundtable Discussions

Feature alongside key opinion leaders to discuss current hot topics and highlight your company's expertise.

Organise Workshops

Demonstrate best practice within the industry in front of your peers with case studies from your clients.

Exhibit your Products & Solutions

Promote your offerings and ensure delegates know where to find you with a prominent brand presence in the exhibition hall.

Digital Marketing & Lead Generation

Accessing the Oxford Global database, amplify your thought leadership and branding messaging through our digital content initiatives.





DRIVE INNOVATION & ACCELERATE RESEARCH Who Is Partnering?

Platinum Sponsors



Gold Sponsors



















Silver Sponsors



















BROCHURE CONTENTS

Welcome

Benefits of **Attending**

Sponsors

Special Event Features

Agenda at a Glance

Featured Speakers: Discovery

Featured Speakers: Formulation

All Speakers

Full **Programme:** Day One

Full **Programme:** Day Two

Venue Information

Book Now



At Oxford Global, our mission is to curate personalised experiences that foster community and inspire innovation.

We believe in the power of networking, connection, and knowledge to deliver quality products and services that exceed expectations. Partnering with Oxford Global means having a dedicated team committed to helping you achieve your goals and navigating the industry's ever-changing landscape.

Arrange 1-1 Meetings

Benefit from guaranteed one-to-one face time with your key prospects, with detailed pre-meeting information provided to enable effective and productive conversations.

Speaking Opportunities

Showcase your company's recent work to a relevant and highly engaged audience.

✓ Host Panel & Roundtable Discussions

Feature alongside key opinion leaders to discuss current hot topics and highlight your company's expertise.

Organise Workshops

Demonstrate best practice within the industry in front of your peers with case studies from your clients.

Exhibit your Products & Solutions

Promote your offerings and ensure delegates know where to find you with a prominent brand presence in the exhibition hall.

Digital Marketing & Lead Generation

Accessing the Oxford Global database, amplify your thought leadership and branding messaging through our digital content initiatives.





DRIVE INNOVATION & ACCELERATE RESEARCH Who Is Partnering?

Bronze Sponsors















Network & Program Sponsors















BIOGNOSYS





nomic nuclera









Start Up Zone

















BROCHURE CONTENTS

Welcome

Benefits of **Attending**

Sponsors

Special Event Features

Agenda at a Glance

Featured Speakers: Discovery

Featured Speakers: Formulation

All Speakers

Full **Programme:** Day One

Full **Programme:** Day Two

Venue Information

Book Now

Linked in



CONTENTS

BROCHURE

Big Attendance Meets Intimate Connections



Received the 2023 **American Chemical Society** (ACS) Philadelphia Section Award

'Innovation & Breakthroughs Under the Stars' Garden Party

Join us for our 'Innovations & Breakthroughs Under the Stars' Garden Party at the end of Day 1 at the Eventide Gardens, Sheraton San Diego by the Marina. This is your chance to mix and mingle with the brightest minds in the industry in a vibrant, open-air setting, complete with gourmet food stations, refreshing drinks, and a relaxed garden-party vibe.

Whether you're coming to connect, unwind, or simply enjoy a summer evening, this is the can't - miss celebration of the season, all under the



Day 1 Opening Keynote Address: The Single-Molecule Revolution Makes Landfall In Drug Discovery: Where We Are Now & What's To Come

- STEVE TURNER, Chief Executive Officer, Pangio Biosystems & Former Founding Chief Executive Officer, PacBio
- Don't miss Steve opening the event with his talk at 9:15 on Day 1.

Day 2 Opening Keynote Address: How 'Proximity **Medicines' Are Transforming Pharmacotherapy**

- RAY DESHAIES, Former Senior Vice President of Global Research, Amgen
- Ray's talk will be taking place at 9:00 on Day 2.

Interactive Sessions

Get up close and personal with industry trailblazers in our variety of roundtables and panel discussions. Hear firsthand how leaders are tackling big challenges in implementing novel technologies such as AI/ML, driving innovation, and shaping the future of drug development. Expect meaningful debates, bold ideas, and valuable insights you won't find in a typical presentation

The Start Up Zone Program

Step into the spotlight at Discovery & Development US 2025's Start-Up Zone – a dynamic launchpad for 10+ cutting-edge start-ups in drug discovery and development. Pitch your vision, showcase your tech, and connect with key players driving innovation. From Al-driven discovery to lab automation and next-gen therapeutics, this is your stage to shine.

Welcome

Benefits of **Attending**

Sponsors

Special Event Features

Agenda at a Glance

Featured Speakers: Discovery

Featured Speakers: Formulation

All Speakers

Full **Programme:** Day One

Full **Programme:** Day Two

Venue <u>Information</u>

Book Now



Program Agenda at a Glance

Explore Discovery & Development US 2025: North America's leading event for drug discovery, preclinical development and formulation returns in October 2025, uniting experts in both small molecule and biologics drug development to deliver first-in-class drugs at pace.

		Day One		Day Two
Cross- Programme Features	Opening Keynote Address Interactive Networking Breaks: Poster Presentations & 1-2-1 Meetings Networking Drinks Reception Garden Party		Opening Keynote Address Breakfast Roundtables Interactive Networking Breaks: Poster Presentations & 1-2-1 Meetings	
Drug Discovery	Track 1	Novel Target ID for Small & Large Molecules	Track 1	Part 1: DMPK, Pharmacology & Safety Part 2: Hit Identification, Optimization & Screening
Program	Track 2	Medicinal & AI-Guided Computational Chemistry	Track 2	Part 1: Implementing Lab Automation & Digitization Part 2: Degraders & Molecular Glues
Formulation &	Track 3	Small Molecule Formulation	Track 3	Large Molecule Formulation
Delivery Program	Track 4	Part 1: Large Molecule Delivery & RNA Design Part 2: Large Molecule Formulation & RNA Design	Track 4	Part 1: Small Molecule Delivery Part 2: Large Molecule & RNA Delivery
Start Up Zone	Afte	ernoon: Start-Up Zone Presentations		

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Special Event Features

Agenda at a Glance

Featured
Speakers:
Discovery

Featured
Speakers:
Formulation

All Speakers

Full
Programme:
Day One

Full
Programme:
Day Two

Venue Information

Book Now



AGENDA AT A GLANCE

Discovery & Automate US

Join leading scientific experts through our annual Discovery and Automation & Robotics programs, addressing critical strategies, scientific breakthroughs and the latest technological advancements in novel modalities & computational tools, new case studies on PROTACs & molecular glues and the utilization of AI, robotics & automation in early R&D.

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- PROTACs
- Medicinal Chemistry
- Lead Generation
- Screening
- Small Molecule Discovery

- · AI/ML
- Lab Automation
- Digital Transformation
- DMPK
- Molecular Glues

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Formal 1:1 meeting opportunities will be available to arrange prior to the event which take place during the dedicated networking breaks covering:

- Library Optimisation
- Screening Technologies
- Target Validation
- Organoid Discovery
- Protein Degradation Tools

- Automation
- Computational Tools
- Animal Models
- Inhibitor Discovery
- AI/ML

Day One

Day 1 Track 1: Novel Target ID for Small & **Large Molecules**

- Technological advancements for the discovery of novel new targets
- New paradigms beyond the rule of five
- Al to unblock drug discovery, drug repurposing and target validation
- Complementary use of genomic & proteomic technologies with Al
- 3D organoids to pursue 'undruggable' targets
- How can we streamline translation of basic scientific findings into human applications
- Disease-centric biologic insights and dealing with increasingly complex target biology
- New modalities that go after the target identification phase: ADCs, cell therapies, bispecific antibodies
- Validating novel biomarkers to improve success in early drug development

Track 2: Medicinal & Al-Guided Computational Chemistry

- New approaches in computer-aided drug design
- Quantum mechanics in drug discovery
- · Fragment & structure-based drug design, including Cryo-EM applications
- Biocatalysis for pharmaceutical synthesis & drug discovery
- · Utilising high-quality chemical probes
- Progressing 'intractable targets' from a medicinal chemistry & DMPK perspective

Day Two

Track 1:

Part 1: DMPK, Pharmacology & Safety

- Predicting & Measuring PK/PD, including computational models
- Novel models for ADME-Tox research & disease modelling - including organ-on-a-chip, organoids, iPSC-derived cells and humanized mouse models
- Development of animal efficacy models
- Safety assessment & safety pharmacology
- Human dose prediction

Part 2: Hit Identification, Optimization & Screening

- Molecular target-based screening
- Affinity/binding assays for hit ID, including mass spectrometry, biophysical approaches, DNA-encoded libraries, high content imaging &

Track 2:

Part 1: Implementing Lab Automation & Digitization

- Automating laboratory workflows through discovery & development to improve productivity
- Lab robotics & tools for drug discovery Digital transformation & digitization strategies

Part 2: Degraders & Molecular Glues

- using:
- » Screening technologies
- » Proteomics & mass spec
- » Biophysical techniques
- New technologies & platforms for glue discovery
- Rational design & mechanistic understanding of molecular glues

- Phenotypic screening
- computational screening

- · Discovery & optimization of novel degraders
- PROTACs & targeted protein degradation
- Exploring new degradation pathways & modalities

BROCHURE CONTENTS

Welcome

Benefits of **Attending**

Sponsors

Special Event Features

Agenda at a Glance

Featured Speakers: Discovery

Featured Speakers: Formulation

All Speakers

Full **Programme:** Day One

Full **Programme:** Day Two

Venue Information

Book Now



AGENDA AT A GLANCE

Formulation & Delivery

Join world-leading experts in drug product development and delivery for this in-person meeting on the West Coast's scientific hub, San Diego. You'll learn about the latest advancements in the formulation of large and small molecule-based drugs, developments in RNA and explore the innovations in the delivery of complex and challenging therapeutics.

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- Formulation Science
- Drug Delivery
- Bioanalysis
- Device Development
- RNA Delivery

- Pharmaceutics
- Pharmaceutical Sciences
- Nanomedicine
- Drug Formulation
- Sustainable Formulation

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers.

Formal 1:1 meeting opportunities will be available to arrange prior to the event which take place during the dedicated networking breaks covering:

- Contract Development
- Characterization Tools
- Raw Materials
- Analytical Services
- Solubility & Stability Testing

- Dosage Forms
- Delivery Devices
- Formulation Development
- Quality Control
- Controlled Release

Day One

Track 3: Small Molecule Formulation

- Overcoming challenges in small molecule drug formulation and delivery including non-oral routes
- Recent advances to improve bioavailability: permeability, solubility
- Digitalization and automation of processes: Al/ML, in-silico modelling

Track 4: Part 1: Large Molecule Delivery & RNA Design

- Moving beyond injectable delivery of biologics including inhalation
- Overcoming oral delivery challenges
- Innovative technologies developing personalized drug delivery systems
- Novel strategies for RNA design
- Harnessing inherent potency of peptides with long-acting injectables and depositions

Track 4 Part 2: Large Molecule Formulation & RNA Design

- Overcoming challenges in RNA delivery
- Lipid nanoparticles to deliver RNA

Day Two

Track 3: Large Molecule Formulation

- Innovative formulation strategies for ADCs, cell & gene therapies, peptides and more
- Overcoming challenges in large molecule drug formulation
- Formulating therapies for pre-filled syringe delivery
- Optimizing high dosage biologics

Track 4: Part 1: Small Molecule Delivery

- Oral dosage form improvement
- Novel routes of administration for small molecules: pulmonary, transdermal, topical, ocular, nasal
- Patient-friendly delivery and dosage forms
- Challenges of delivering sustainability

Track 4: Part 2: Large Molecule & RNA Delivery

- Lipid nanoparticles to deliver biologics
- Pre-filled syringes
- Use cases of utilizing viral and nonviral delivery modalities
- Overcoming challenges in RNA delivery
- Advanced techniques for delivery beyond the liver

Welcome

BROCHURE CONTENTS

Benefits of Attending

Sponsors

Special Event Features

Agenda at a Glance

Featured
Speakers:
Discovery

Featured
Speakers:
Formulation

All Speakers

Full
Programme:
Day One

Full
Programme:
Day Two

Venue Information

Book Now



AWARD WINNING SPEAKERS ON BOARD

Shaping Drug Discovery Now

DR. RAY DESHAIES

Former Senior Vice President of Global Research, Amgen

Dr. Deshaies received the 25th Jacob and Louise Gabbay Award in Biotechnology and Medicine for his pioneering work on PROTACs (proteolysis targeting chimeras), a novel approach in targeted protein degradation.

TOR. RICK EWING

Dr. Beth Hoffman, Dr. Rick Ewing, Dr. Ray Deshaies, Dr. Robert Fremeau

Vice President, Head of Chemistry, Rapafusyn Pharmaceuticals

Dr. Ewing was honored with the 2023 American Chemical Society (ACS) Philadelphia Section Award, recognizing his distinguished career in medicinal chemistry.

TOR. ROBERT FREMEAU

Founder & Chief Executive Officer, BrainStorm Therapeutics

Dr. Fremeau serves as the Principal Investigator for a National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I award, focusing on developing a novel Parkinson's disease drug discovery platform.

TOTAL SETH HOFFMAN

President & Chief Executive Officer, Origami Therapeutics, Inc.

Earlier in her career, Dr. Hoffman was awarded the Anna-Monika Foundation Prize for Advancement in Depression Research and an NSF Pre-doctoral Fellowship.

> Click Below to Preview our Award Winning Speaker's **Presentations**

> > Full **Programme:** Day Two

BROCHURE CONTENTS

Welcome

Benefits of **Attending**

Sponsors

Special

Event

Features

Agenda at

a Glance

Featured

Speakers:

Discovery

Featured Speakers:

Formulation

All Speakers

Full **Programme:** Day One

Venue Information

Book Now

🗶 @OGConferences





FEATURED SPEAKERS

Shaping Drug Development Now

ERIC MUNSON,

Professor, Purdue University

IPEC Americas Foundation: Ralph Shangraw Memorial Award 2020

ANDREW GEALL,

Co-Founder & Chief Development Officer, Replicate Bioscience

BINDHU RAYAPROLU,

Director, Research & Development, Regeneron

MARIA WINZELL,

Senior Director Drug Development, Camurus

DIMITRIOS ZISOULIS,

Head of RNA Therapeutics,
Janssen Pharmaceutical Companies of Johnson &
Johnson



BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Special Event Features

Agenda at a Glance

Featured
Speakers:
Discovery

Featured
Speakers:
Formulation

All Speakers

Full
Programme:
Day One

Full Programme: Day Two

Venue Information

Book Now



SPEAKERS ACROSS ALL PROGRAMS

Discovery & Development US

STEVE TURNER

Chief Executive Officer, Pangio Biosystems & Former Founding Chief Executive Officer, PacBio

RAY DESHAIES

Former Senior Vice President of Global Research, Amgen

ROBERT FREMEAU

Founder & Chief Executive Officer, BrainStorm Therapeutics

BETH HOFFMAN

President & Chief Executive Officer, Origami Therapeutics, Inc.

SAM SINAI

Co-Founder & Head of Machine Learning, Dyno Therapeutics

RICK EWING

Vice President, Head of Chemistry, Rapafusyn Pharmaceuticals

STEFANO ZANOTTI

Senior Vice President, Neuromuscular Research, Dyne Therapeutics

DAVID BUCKLER

Executive Director – Research Program Management, Regeneron

PRASHI JAIN

Director, Drug Discovery, Iterion Therapeutics

KAUSHEEK NANDY

Digital Transformation Director – Research, Boehringer Ingelheim

SHANTHI NAGARAJAN

Director, Lilly Small Molecule Discovery, Eli Lilly

JOSH BAUGHMAN

Scientific Director, Bristol Myers Squibb

LEI JIA

Associate Director, Drug Discovery Data Science, Johnson & Johnson

SURENDRA NAYAK

Scientific Associate Director, Bristol Myers Squibb

ABHINAV SHARMA

Translational Human Models Lead, Dermatology/Immunology Discovery, AbbVie

FABIEN VINCENT

Consultant, Former Pharmacology Lab Head, Pfizer

PHIL COX

Research Fellow, Discovery Research, AbbVie

JEAN GE

Patent Attorney, Wolf Greenfield

LAN FONG

President, Berkeley Angel Network

SHUANGWEI LI

Director of Toxicology, Calibr-Skaggs Institute for Innovative Medicines

KATHERIN PATSCH

Director, Drug Discovery, Ellison Medical Institute

TOBIAS RAABE

Director, Translational Genome Editing Laboratory, Perelman School of Medicine, University of Pennsylvania

JOSEPH WU

Professor & Director, Stanford Cardiovascular Institute & Co-Founder, Greenstone Biosciences

JIANQIN LU

John A. & Frances P. Ware Endowed Associate Professor, University of Arizona & Co-Founder, SPH Therapeutics

YUE WEBSTER

Vice President, Model Driven Drug Discovery Platforms, Eli Lilly

PEGGY THOMPSON

Vice President, Head of Biology, Plexium

KISHORE PASIKANTI

Senior Director, DMPK, Grünenthal Group

DAVID LOYND

Chief Executive Officer, EnduRx

PETER HEIFETZ

Chief Executive Officer, Orpro Therapeutics

ANDREW GEALL

Co-Founder & Chief Development Officer, Replicate Bioscience

CRAIG BEHNKE

Executive Vice President, Production & Development, Lumen Bioscience

SEAN SULLIVAN

Vice President of Technology Innovation & Development, Arcturus Therapeutics

MARIA WINZELL

Senior Director Drug Development, Camurus

BINDHU RAYAPROLU

Director, Research & Development, Regeneron

STEPHEN FRAMIL

Corporate Global Head of Accessibility, Merck

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Special Event Features

Agenda at a Glance

Featured
Speakers:
Discovery

Featured
Speakers:
Formulation

All Speakers

Full
Programme:
Day One

Full Programme: Day Two

Venue Information

Book Now





SPEAKERS ACROSS ALL PROGRAMS

Discovery & Development US

DIMITRIOS ZISOULIS

Head of RNA Therapeutics, Janssen Pharmaceutical Companies of Johnson & Johnson

SUNITA YADAV

Associate Director, Novartis

SAYONI RAY

Principal Scientist, Janssen Pharmaceutical Companies of Johnson & Johnson

JITENDRA KUMAR

Lead Scientist, Chemistry & Process Development, Entos Pharmaceuticals

ERIC MUNSON

Professor, Purdue University

ENRICO ZAMBELLI

Sustainable Formulations Project Unit Manager, Chiesi

ELENA LIANG

Principal Research Scientist, AbbVie

ASHLEY DAVALOS

Assistant Director, Ionis

KALPITA MEHTA

Principal Combination Production & Medical Device Expert, Hikma

IACK ROGERS

Director of Neurochemistry, Harvard University

CATHERINE CAHILL

Assistant Professor, Harvard Medical School

SEVERIN SCHNEEBELI

Associate Professor, Purdue University

ANISHA DSOUZA

Research Fellow, Massachusetts Eye and Ear Infirmary, Harvard Medical School

SHILPA THOSAR

Former Executive Director, Cara Therapeutics

RAMESH KASHI

Former Senior Scientific Director, Bristol Myers Squibb

MARK ECCLESTON

Chief Executive Officer, ValiRx

VIVEK GUPTA

Associate Professor, St. John's University

FELIX LAVOIE-PERUSSE

Co-Founder & Chief Commercial Officer, Saguaro Biosciences

FARHAN KHODAEE

Chief Executive Officer, Absentia

BROCHURE CONTENTS

Welcome

Benefits of **Attending**

Sponsors

Special Event Features

Agenda at a Glance

Featured Speakers: Discovery

Featured Speakers: Formulation

All Speakers

Full **Programme:** Day One

Full **Programme:** Day Two

Venue Information

Book Now

X @OGConferences



Day One | October 2 2025

Welcome & Keynote Address Conference Room 4 Coral 4

n8·50

Oxford Global's Welcome Address By Eszter Sutowski Nagy, Senior Production Director



OPENING KEYNOTE ADDRESS & Q&A

The Single-Molecule Revolution Makes Landfall In Drug Discovery: Where We Are Now & What's To Come

STEVE TURNER, Chief Executive Officer, Pangio Biosystems & Former Founding Chief Executive Officer, PacBio



	Q&A session & transition time between conference rooms				
	DRUG DISCOVERY PROGRAM		FORMULATION & DELIVERY PROGRAM		
	NOVEL TARGET ID FOR SMALL & LARGE MOLECULES CONFERENCE ROOM 1 CORAL 1	MEDICINAL & AI-GUIDED COMPUTATIONAL CHEMISTRY CONFERENCE ROOM 2 CORAL 2	SMALL MOLECULE FORMULATION CONFERENCE ROOM 6 SEAGLASS	LARGE MOLECULE DELIVERY & RNA DESIGN CONFERENCE ROOM 3 CORAL 3	
	Morning Track Chair: ABHINAV SHARMA, Translational Human Models Lead, Dermatology/Immunology Discovery, AbbVie	Morning Track Chair TBA	Morning Track Chair: SHILPA THOSAR, Former Executive Director, Cara Therapeutics	Morning Track Chair: ERIC MUNSON, Professor, Purdue University	
	Track Keynote Address: Genetics Driving Discovery: From VelociGene® & VelocImmune® For Therapeutic Antibody Generation To Regeneron Genetics Center's Target Discovery Engine	Track Keynote Address: Targeting TBL1: Molecular & Computational Strategies To Modulate Complex Protein Interactions In Wnt Signaling	Track Keynote Address: Strategies For RNA Therapy For AD/PD With Implications For Treating SARS-CoV-2	Track Keynote Address: Navigating The Next Frontier: Industry Insights Into Emerging Trends In Biologics Delivery	
09:35	 The ability to interrogate and manipulate the genome provides a foundational tool in drug discovery This talk will highlight Regeneron's approaches using VelociGene® and VelocImmune® technology platforms in addition to the Regeneron Genetics Center for target discovery and therapeutic development 	 This talk highlights mechanistic studies describing the inhibition of TBL1 by tegavivint and the development of second-generation small-molecule inhibitors using structural biology and predictive computational approaches Tegavivint is a small-molecule inhibitor of TBL1 that is currently in clinical trials for multiple oncology indications. Using in silico predictive modeling, we have identified a series of novel small molecules that bind to TBL1 and inhibit Wnt signaling. We will present novel strategies employed to identify these compounds and discuss the structural studies that guided lead optimization against this complex protein target 	We reported that the broad-acting Alzheimer's disease clinical drug Posiphen inhibited translation of the amyloid precursor protein as well as the mRNA encoding alpha-synuclein, the major culprit protein of Parkinson's disease & the Huntingtin protein. However, our new pipeline of translation blockers seeks to prevent neurodegeneration with potent drugs that interfere at higher selectivity with these 5'untranslated regions of the neurodegenerative disease-associated transcripts, i.e. the APP/ amyloid of AD and PD specific asyn. Recently, we discovered a line of therapy to inhibit APP translation linked to providing RNA-directed inhibitory actions to limit COVID by lowering the translation rates of the replicase in SARS-CoV-2.	Biologics, which include complex molecules like proteins, monoclonal antibodies, and gene therapies, are revolutionizing modern medicine. As the industry continues to innovate, biologics delivery systems are evolving to meet the growing demand for precision, efficiency, and patient-centric care. This presentation explores the emerging trends shaping the future of biologics delivery, focusing on cutting-edge advancements, challenges, and opportunities.	
	DAVID BUCKLER, Executive Director – Research Program Management, Regeneron	PRASHI JAIN, Director, Drug Discovery, Iterion Therapeutics	CATHERINE CAHILL, Assistant Professor, & JACK ROGERS, Director of Neurochemistry, Harvard University	BINDHU RAYAPROLU, Director, Research & Development, Regeneron	
10:00					
- 11:00	1-2-1 Meetings x3		Poster Displays Poster Displays		

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Special Event Features

Agenda at a Glance

Featured
Speakers:
Discovery

Featured
Speakers:
Formulation

All Speakers

Full
Programme:
Day One

Full
Programme:
Day Two

Venue Information

Book Now

DRUG DISCOVERY PROGRAM

FORMULATION & DELIVERY PROGRAM

NOVEL TARGET ID FOR SMALL & LARGE MOLECULES CONFERENCE ROOM 1 CORAL 1

MEDICINAL & AI-GUIDED COMPUTATIONAL CHEMISTRY CONFERENCE ROOM 2 CORAL 2

SMALL MOLECULE FORMULATION **CONFERENCE ROOM 6 SEAGLASS**

LARGE MOLECULE DELIVERY & RNA DESIGN **CONFERENCE ROOM 3 CORAL 3**

Solution Provider Presentation

Solution Provider Presentation

Solution Provider Presentation



Senior Representative, **Pfanstiehl**

Solution Provider Presentation

11:00

11:50

12:15

13:35

For sponsorship opportunities please contact sponsorship@oxfordglobal.com

> MICHAEL BELLUCCI, Senior Director of R&D, Xtalpi

Xtal?i

Senior Representative,

Q&A session & transition time between conference rooms

Almac

Al-Powered Human Brain Organoid Platform To Transform CNS Drug Discovery

- Pioneering a new paradigm in CNS drug discovery
- Integrating patient-derived brain organoids with Al to accelerate therapeutic discovery
- Building AI foundation models to map diseaserelevant gene networks
- Deploying biomarker-based screening to identify efficacious compounds in human brain disease models at the outset of drug discovery
- Delivering a scalable platform with broad applicability across complex neurodevelopmental and neurodegenerative disorders

ROBERT FREMEAU, Founder & Chief Executive

BrainStorm Therapeutics

Chemical Space Generation, Exploration, **And Visualization**

The number of theoretically possible drug-like molecules is vast and estimated to be >1060. Currently it is not practically feasible to enumerate such vast numbers, however it is possible to use abbreviated methods that encode the entirety of space using reaction SMARTS and associated monomer building blocks. This talk will focus on how we used such a method to generate and explore Nebula, AbbVie's UL chemical space.

How Digital Accessibility Is Critical For Digital Health Solutions

- Personalized drug delivery systems
- Digital accessibility
- Formulation considerations for digital health soultions

Polymeric Carriers Enabling Multi-Route Non-Invasive Delivery Of Large Therapeutic Molecules

- Understand the key challenges and physiological barriers associated with non-invasive delivery of large molecule therapeutics
- Explore the design principles and material considerations behind engineering multifunctional carriers
- Evaluate preclinical data demonstrating the pharmacokinetic, biodistribution, and therapeutic performance of these engineered carriers

PHIL COX, Research Fellow, Discovery Research,

STEPHEN FRAMIL, Corporate Global Head of Accessibility, Merck

VIVEK GUPTA, Associate Professor, St. Iohn's University

Q&A session & transition time between conference rooms

Gold Solution Provider Presentation

For sponsorship opportunities please contact

sponsorship@oxfordglobal.com

Tracking Medicinal Chemistry Project Beyond Design

Even beyond compound prioritization challenges, medicinal chemistry projects face further hurdles. This talk focuses on the Project Progress Report, a new approach to track development and identify any critical issues to streamline the path to discovery.



JEREMY MALERICH, Application Scientist Chemaxon

Solution Provider Presentation

Senior Representative,

Aprecia

Development Of An Influenza LNP-mRNA Vaccine With Tailored Immunogenicity

We will present advances in creating ionizable lipids with tunable immunogenic profiles and their use in creating vaccines favoring cellular or humoral responses. Finally, a case study of a mRNA vaccine against influenza shall be discussed.



SYED REZA, Scientific and Sales Consultant, **NOF Corporation**

EXECUTE LUNCH BREAK



1-2-1 Meetings x4







CONTENTS

BROCHURE

Welcome

Benefits of **Attending**

Sponsors

Special Event **Features**

Agenda at a Glance

Featured Speakers: Discovery

Featured Speakers: Formulation

All Speakers

Full **Programme:** Day One

Full **Programme:** Day Two

Venue Information

Book Now

Linked in X @OGConferences



AbbVie



Poster Displays P

	Day One October 2 2025				
	DRUG DISCOVERY PROGRAM		FORMULATION & DELIVERY PROGRAM		
	NOVEL TARGET ID FOR SMALL & LARGE MOLECULES	MEDICINAL & AI-GUIDED COMPUTATIONAL CHEMISTRY	SMALL MOLECULE FORMULATION	LARGE MOLECULE DELIVERY & RNA DESIGN	
	CONFERENCE ROOM 1 CORAL 1	CONFERENCE ROOM 2 CORAL 2	CONFERENCE ROOM 6 SEAGLASS	CONFERENCE ROOM 3 CORAL 3	
	Afternoon Track Chair: TOBIAS RAABE, Director, Translational Genome Editing Laboratory, Perelman School of Medicine, University of Pennsylvania	Afternoon Track Chair: KATHERIN PATSCH, Director, Drug Discovery, Ellison Medical Institute	Afternoon Track Chair: SHILPA THOSAR, Former Executive Director, Cara Therapeutics	Afternoon Track Chair: ERIC MUNSON, Professor, Purdue University	
	Gold Solution Provider Presentation	Practical Steps To Maximize Al Value In Drug Discovery - From Algorithm To Adoption Maximizing Al's impact in drug discovery requires practical tools that empower scientists. It also necessitates a focus on the implementation of proven algorithms and organizational change. Using case study examples from our StarDrop and Cerella platforms we show how Al's value can be	Solution Provider Presentation	Small Particles, Big Impact: Maximizing Therapeutic Impact Through Nanoparticle-Enabled Delivery Learn how key drug delivery challenges such as targeting, bioavailability, and circulation time can be overcome through nanoparticle-enabled formulations.	
13:35	For sponsorship opportunities please contact sponsorship@oxfordglobal.com	Cerella platforms we show how Al's value can be demonstrated.	X Xtal⊋i	FORTIS	
		Opcior idi i i	7. Atairi	LIFE SCIENCES	
		MATTHEW SEGALL, Chief Executive Officer, Optibrium	Senior Representative, Xtalpi	JESS WIDMAN, Senior Product Development Scientist, Fortis Life Sciences	
		Q&A session & transition tin	ne between conference rooms		
	The FORCE™ Platform Delivers Functional Improvement In Neuromuscular Diseases	How AI Powers A New Age Of Genetic Agency	Formulation Of CLX-001, A Next Generation Oncolytic Peptide For Cancer Therapy	FAST Protein-Enabled Proteolipid Vehicles: A Novel Platform For Advanced Gene Therapy Delivery	
14.00	The FORCE™ platform demonstrates delivery of oligonucleotides & achieved clinical translation in the ACHIEVE trial for DM1 & DELIVER trial for DMD, opening an opportunity for the treatment of FSHD. In preclinical models of FSHD, DYNE-302, a Fab-siRNA conjugate, achieved robust muscle delivery & target engagement, leading to appreciable benefit on muscle function & myofiber pathology.	Genetic medicines are poised to transform treatment across many unaddressed diseases. This talk highlights how AI is accelerating this future by replacing costly experiments with computation, rapidly generating and testing hypotheses, and integrating diverse biological data. These advances are enabling genetic medicines to be designed and optimized with unprecedented precision, getting them closer to	 CLX001 – a novel oncolytic peptide Membrane-lytic peptide based intravenous nanotherapeutics Oncolytic peptides – synergistic agents for small molecule and Immunotherapy 	 FAST protein integration into proteolipid vehicles (PLVs) enables efficient delivery of therapeutic DNA and RNA directly into target cell cytoplasm by overcoming endocytosis barriers FAST protein-enabled PLVs demonstrate broad biodistribution and low immunogenicity in animal models, maintaining sustained gene expression for extended periods without 	

STEFANO ZANOTTI, Senior Vice President, Neuromuscular Research,

Dyne Therapeutics

14:00 myofiber pathology.

hypotheses, and integrating diverse biological data. These advances are enabling genetic medicines to be designed and optimized with unprecedented precision, getting them closer to impact in a wide range of new applications.

SAM SINAI, Co-Founder & Head of Machine Learning, **Dyno Therapeutics**

MARK ECCLESTON, Chief Executive Officer, **ValiRx**

- biodistribution and low immunogenicity in animal models, maintaining sustained gene expression for extended periods without significant inflammatory responses
- •The PLV platform, leveraging FAST proteins, offers a durable and versatile system capable of delivering large genetic payloads, including CRISPR-Cas9, with significant implications for future gene therapies

JITENDRA KUMAR, Lead Scientist, Chemistry & Process Development,, **Entos Pharmaceuticals**

Q&A session & transition time between conference rooms

BROCHURE CONTENTS

Welcome

Benefits of **Attending**

Sponsors

Special Event Features

Agenda at a Glance

Featured Speakers: Discovery

Featured Speakers: Formulation

All Speakers

Full **Programme:** Day One

Full **Programme:** Day Two

Venue Information

Book Now

Day One | October 2 2025

DRUG DISCOVERY PROGRAM

FORMULATION & DELIVERY PROGRAM

NOVEL TARGET ID FOR SMALL & LARGE MOLECULES CONFERENCE ROOM 1 CORAL 1

Is There Any Open Space Left In Target **Identification & Al Drug Discovery?**

• FRONTEO drug discovery support solution called Drug Discovery AI Factory drives First in Class drugs, maximizes value of customer assets &

- accelerates drug discovery research
 Unique analysis methods using the gene network drawn by KIBIT are excellent at extracting target molecules with a higher probability of success from the target molecules predicted by KIBIT FRONTEO's biologists using KIBIT uncover unknown relationships between disease and genes with few or no hits in PubMed and generate hypotheses of novel targets
- Highly novel pancreatic cancer target molecule candidate extracted by KIBIT demonstrated cell proliferation inhibitory effect



HIROYOSHI TOYOSHIBA, Chief Scientific Officer & Director, **Fronteo**

MEDICINAL & AI-GUIDED COMPUTATIONAL CHEMISTRY CONFERENCE ROOM 2 CORAL 2

Accelerating BRPF1b Hit Identification With BioPhysical And Active Learning Screening (BioPALS)

Concept Life Sciences has developed BioPALS, an innovative, lean and versatile hit identification platform combining Al-powered virtual screening with cutting-edge biophysical technologies. Herein we present novel BRPF1b hits, identified using the BioPALS workflow.

SMALL MOLECULE FORMULATION CONFERENCE ROOM 6 SEAGLASS

Solution Provider Presentation

LARGE MOLECULE FORMULATION & RNA **DESIGN CONFERENCE ROOM 3 CORAL 3**

Solution Provider Presentation



JAMIE STOKES, Associate Chemistry Director, **Concept Life Sciences**



Senior Representative, **Crystal Pharmatech**



Senior Representative, **SP Scientific Products**

🗣 AFTERNOON BREAK 🕏



1-2-1 Meetings x3



Poster Displays P



Solution Provider Presentation

14:50

15:50

15:50

Use Of Virtual Libraries To Accelerate Drug Discovery: A Case Study

The use of virtual libraries in Drug Discovery has shown increased popularity in recent years alongside the development of more powerful search and evaluation software. Here we will describe the design of the eMolecules/Synple Virtual libraries and a case study of its use in a drug discovery program.

eMolecules

DAVID JAMES, Senior Vice President Scientific Business Development, **eMolecules**

Enhancing Drug Solubility & Bioavailability Through Novel Formulation Technologies: ASD, Lipid-**Base System, & Permeability Enhancers Application**

This presentation will explore innovative formulation strategies to enhance drug solubility and bioavailability, focusing on ASD technology, lipid-based system, and permeability enhancers. These cutting-edge approaches aim to overcome challenges associated with poorly soluble drugs, improving their absorption and therapeutic efficacy. By examining the mechanisms benefits, and real-world applications of these techniques, the talk will highlight how these strategies can revolutionize drug development.



IVY HUANG, Senior Director Formulation, BioDuro

Excipients for Biomolecule Formulation

Biomolecule formulations are prone to instability and aggregation. MilliporeSigma provides highquality excipients that strengthen stability and support robust drug performance at every step



LYNDON L. E. SALINS, Senior Technical Application Specialist, Formulation & Drug Delivery, Millipore Sigma

Linked in

Senior Representative, Collaborative Drug Discovery, Inc.

CDD.VAULT®

COLLABORATIVE DRUG DISCOVERY

Q&A session & transition time between conference rooms

Formulation All Speakers

BROCHURE CONTENTS

Welcome

Benefits of

Attending

Sponsors

Special

Event **Features**

Agenda at a Glance

Featured Speakers:

Discovery

Featured

Speakers:

Full **Programme:** Day One

Full **Programme:** Day Two

Venue

Information

Book Now

X @OGConferences

Day One | October 2 2025

DRUG DISCOVERY PROGRAM

FORMULATION & DELIVERY PROGRAM

NOVEL TARGET ID FOR SMALL & LARGE MOLECULES

CONFERENCE ROOM 1 CORAL 1

START UP ZONE

CONFERENCE ROOM 2 CORAL 2 CONFERENCE ROOM 6 SEAGLASS LARGE MOLECULE FORMULATION & RNA DESIGN

CONFERENCE ROOM 3 CORAL 3

Complex In Vitro Models For Drug Discovery & Development Of Immunological Disorders

- •Advances in next-generation platforms for immune-related drug discovery
- Novel strategies to model complex immunological pathways in vitro

16:15

16:40

 Emerging opportunities for therapeutic development in immunological disorders

ABHINAV SHARMA, Translational Human Models Lead, Dermatology/Immunology Discovery, **AbbVie**

INTERACTIVE

PANEL DISCUSSION:

The Status Of AI/ML In Drug Discovery: Where Are We And Where Are We Going?

- Examples of successful application / acceleration of discovery programmes using Al/ML
- Best practices
- Limitations & challenges

Panellists:

PHIL COX, Research Fellow, Discovery Research AbbVie

MATTHEW SEGALL, Chief Executive Officer, Optibrium

KATHERIN PATSCH, Director, Drug Discovery, **Ellison Medical Institute**

Q&A session & transition time between conference rooms

Stem Cells, Genomics & Al For Drug Discovery

- Learn recent announcements of 'New Alternative Methodologies' by FDA, NIH and EPA
- · Learn how stem cells, organoids, genomics & Al can be integrated for drug discovery

Start Up Zone Presentations (10 min) Presentation 1: Profiling Drugs With Images: De-Risking The Pipeline With **New Live-Cell Insights**

- Traditional omics methods can miss critical drug annotations. They fail to capture the ultimate manifestation of drug effects, and cannot probe cells in the manifestation of drug effects, physiologically related the print personnel of the pe relevant environment.
- Live-cell image-based profiling overcomes these limitations by capturing a holistic, unperturbed cell response.
- This provides drug discovery leaders with a powerful approach for better drug insights FELIX LAVOIE-PERUSSE, Co-Founder and Chief Commercial Officer, Saguaro Biosciences



(10 min) Presentation 2: Building The First, Whole-Organism, Al-Based, Pre-Clinical **Platform**

FARHAN KHODAEE, Chief Executive Officer, **Absentia**

absentia.

INTERACTIVE

WORKSHOP:

Tides Analytical Development: Innovations In Oligonucleotides & Peptide Analysis & Delivery

SMALL MOLECULE FORMULATION

Presentation 1: New Computational & Experimental Insight Into Oral Peptide Delivery With Permeation Enhancers

Oral peptide formulations improve patient compliance by eliminating injections, especially in early-stage disease where long-term adherence is crucial. Permeation enhancers have transformed oral delivery by enabling peptides to cross the intestinal barrier safely, allowing effective systemic absorption. Despite these advances, further refinement and understanding of enhancer mechanisms are needed. This presentation offers new insights into their function, supported by constant pH molecular dynamics simulations and experimental data from relevant model systems.

SEVERIN SCHNEEBELI, Associate Professor, **Purdue University**

Presentation 2: Universal Assay Determination Method For Antisense Oligonucleotides Via Slope Spectroscopy

Developed a universal assay method for antisense oligonucleotide (ASO) drug products using slope spectroscopy with the SoloVPE system, offering a simple, robust alternative for in-process control (IPC) of ASO concentration. The method was optimized across multiple parameters and validated for linearity, accuracy, precision, reproducibility, and robustness—with excellent performance across different ASO chemistries and formulations. The method proved transferable across sites (Ionis and CMOs), is independent of specific ASO attributes, and was recognized as a universal IPC assay platform for broad application in ASO drug product manufacturing.

ASHLEY DAVALOS, Assistant Director, Ionis

WORKSHOP:

& Delivery

Presentation 1: Translation Of An Optimized Self-Replicating RNA (srRNA) Platform With An Expanded Clinical Therapeutic Index

- Demonstration that next generation srRNA vectors with optimized non-coding regions achieve protective immunity at doses up to 1,000,000-fold lower than conventional mRNA in preclinical models of influenza and rabies
- improved srRNA vector encoding the rabies virus glycoprotein and encapsulated in a novel lipid nanoparticle. Demonstrating the high therapeutic index of next generation srRNA vectors and the feasibility of both low dose and single dose administration for vaccine applications
- Potential of srRNA for applications beyond vaccines

ANDREW GEALL, Co-Founder & Chief Development Officer, **Replicate Bioscience**

Presentation 2: Lipid Nanoparticle (LNP) Formulation & mRNA Manufacturing **Development**

- Development of an ionizable lipid library
- Drug product formulation development
- Optimization of drug substance manufacturing unit operations

SEAN SULLIVAN, Vice President of Technology Innovation & Development, **Arcturus Therapeutics**

INTERACTIVE

The Changing Landscapes Of RNA Design

- Phase I clinical data with RBI-4000, an

Full **Programme:** Day One

BROCHURE CONTENTS

Welcome

Benefits of

Attending

Sponsors

Special

Event

Features

Agenda at

a Glance

Featured

Speakers:

Discovery

Featured

Speakers:

Formulation

All Speakers

Full **Programme:** Day Two

Venue Information

Book Now

Linked in X @OGConferences

JOSEPH WU, Professor & Director, Stanford Cardiovascular Institute & Co-Founder, **Greenstone Biosciences**

Q&A session & transition time between conference rooms

DRUG DISCOVERY PROGRAM

NOVEL TARGET ID FOR SMALL & LARGE MOLECULES

CONFERENCE ROOM 1 CORAL 1

Lipid Nanoparticles Enable Efficient Cell Type Specific Gene Targeting In A Patient Liver - Derived Fibrosis Model

- •We developed a lipid nanoparticle-based platform that enables >80% gene targeting efficiency in non-dividing hepatocytes, cholangiocytes, myofibroblasts, and proinflammatory macrophages within a fully human 3D organoid model in just two days. This system supports cell type-specific knockdown, overexpression, or editing for multi-target liver fibrosis therapies
- Our modular, patient-derived organoid model allows parallel screening across diverse fibrotic liver diseases, including MASH, cholangiopathies, alcohol-related cirrhosis, and viral fibrosis

TOBIAS RAABE, Director, Translational Genome Editing Laboratory, Perelman School of Medicine,

University of Pennsylvania

& LARGE START UP ZONE

CONFERENCE ROOM 2 CORAL 2

Start Up Zone Presentations (10 min) **Presentation 1: Si-Care Bio**



(10 min) Presentation 2: Athens LifeTech Park



Q&A session & transition time between conference rooms

INTERACTIVE

PANEL DISCUSSION: Advanced Tools & Tech For Drug Discovery

- Making use of all the datasets
- New alternative methods

Moderator: LAN FONG, President, **Berkeley Angel Network**

Panellists:

DAVID BUCKLER, Executive Director – Research Program Management, **Regeneron**

SAM SINAI, Co-Founder & Head of Machine Learning, **Dyno Therapeutics**

JOSEPH WU, Professor & Director, **Stanford Cardiovascular Institute** & Co-Founder, **Greenstone Biosciences**

ABHINAV SHARMA, Translational Human Models Lead, Dermatology/Immunology Discovery, **AbbVie** (10 min) Presentation 1: Insilico Prediction Of In-Vivo Efficacy At The Drug Design Stage



(10 min) Presentation 2: Ontologic



Moderator: ERIC MUNSON, Professor, **Purdue**

University **Panellists:**

KALPITA MEHTA, Principal Combination Production & Medical Device Expert, **Hikma**

ASHLEY DAVALOS, Assistant Director, Ionis

SEVERIN SCHNEEBELI, Associate Professor, **Purdue University**

SAYONI RAY, Principal Scientist, Janssen Pharmaceutical Companies of Johnson & Johnson

FORMULATION & DELIVERY PROGRAM

SMALL MOLECULE FORMULATION CONFERENCE ROOM 6 SEAGLASS

INTERACTIVE

WORKSHOP (CONT.): Tides Analytical Development: Innovations In Oligonucleotides & Peptide Analysis & Delivery

Panel Discussion: Exploring Alternative Route Of Tides Delivery

- Oral delivery of peptides
- Nasal delivery
- Delivering oligos beyond the liver
- Pre-filled syringes
- Sustainability and stability considerations

DELIVERT FROOKAM

LARGE MOLECULE FORMULATION & RNA
DESIGN
CONFERENCE ROOM 3 CORAL 3

INTERACTIVE

WORKSHOP (CONT.): The Changing Landscapes Of RNA Design & Delivery

Panel Discussion: Novel Strategies For RNA Design & Delivery

- RNA Interference (RNAi)
- microRNA
- Antisense Oligonucleotides
- •circRNA

Moderator: SUNITA YADAV, Associate

Director. **Novartis**

Panellists:

DIMITRIOS ZISOULIS, Head of RNA Therapeutics, Janssen Pharmaceutical Companies of Johnson & Johnson

ANDREW GEALL, Co-Founder & Chief Development Officer, **Replicate Bioscience**

SEAN SULLIVAN, Vice President of Technology Innovation & Development, **Arcturus**Therapeutics

Q&A session & transition time between conference rooms

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Special Event Features

Agenda at a Glance

Featured
Speakers:
Discovery

Featured
Speakers:
Formulation

All Speakers

Full
Programme:
Day One

Full Programme: Day Two

Venue Information

Book Now

Day One | October 2 2025

DRUG DISCOVERY PROGRAM

FORMULATION & DELIVERY PROGRAM

NOVEL TARGET ID FOR SMALL & LARGE MOLECULES CONFERENCE ROOM 1 CORAL 1

INTERACTIVE USSION: Advanced Tools & Tech For Drug Discovery

- · Making use of all the datasets
- New alternative methods

Moderator: LAN FONG, President, **Berkeley Angel Network**

Panellists:

DAVID BUCKLER, Executive Director – Research Program Management, **Regeneron**

SAM SINAI, Co-Founder, Head of Machine Learning, **Dyno Therapeutics**

JOSEPH WU, Professor & Director, **Stanford Cardiovascular Institute** & Co-Founder, **Greenstone Biosciences**

ABHINAV SHARMA, Translational Human Models Lead, Dermatology/Immunology Discovery, **AbbVie** START UP ZONE

CONFERENCE ROOM 2 CORAL 2

(10 min) Presentation 1: OCMS Bio



(10 min) Presentation 2: Epigenetic Therapies For Next-Generation Pain Therapeutics & Beyond

FERNANDO ALEMAN, Co-Founder & Chief Scientific Officer, Navega Therapeutics



SMALL MOLECULE FORMULATION

CONFERENCE ROOM 6 SEAGLASS

INTERACTIVE USSION:

Digitization & Automation Of Formulation Processes

- Developments with AI within formulation
- Utilising the latest technology
- •Al/ML for personalized formulation

Moderator: SHILPA THOSAR, Former Executive Director, **Cara Therapeutics**

Panellist:

STEPHEN FRAMIL, Corporate Global Head of Accessibility, **Merck**

VIVEK GUPTA, Associate Professor, **St. John's University**

KRISTA DIAZ, Director of Business Development, Almac Group

LARGE MOLECULE FORMULATION & RNA DESIGN

CONFERENCE ROOM 3 CORAL 3

LOCATED IN CORAL FOYER ROUNDTABLE DISCUSSION 1:

INTERACTIVE

LNP Formulation Development Of RNA & DNA

- Tailoring LNPs for different administration routes
- Optimizing formulations

Moderator: SAYONI RAY, Principal Scientist, Janssen Pharmaceutical Companies of Johnson & Johnson

ROUNDTABLE DISCUSSION 2:

IP Considerations In Early Discovery & Development

- Establishing effective IP infrastructure
- Crafting a coherent IP strategy that aligns with early discovery & development activities
- •Building a "diligence ready" IP portfolio

Moderator: JEAN GE, Patent Attorney, **Wolf Greenfield**

18:20

Grab a drink & make your way to the Garden Party

Section Classes of Day one

Innovations & Breakthroughs Under the Stars Garden Party at Eventide Gardens, Sheraton San Diego

Join us for our 'Innovations & Breakthroughs Under the Stars' Garden Party at the end of Day 1 at the Eventide Gardens, Sheraton San Diego by the Marina. This is your chance to mix and mingle with the brightest minds in the industry in a vibrant, open-air setting, complete with gourmet food stations, refreshing drinks, and a relaxed garden-party vibe.

Whether you're coming to connect, unwind, or simply enjoy a summer evening, this is the can't - miss celebration of the season, all under the California night sky.

Welcome Address by Dr Rick Ewing, Vice President, Head of Chemistry, Rapafusyn Pharmaceuticals



BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Special Event Features

Agenda at a Glance

Featured
Speakers:
Discovery

Featured
Speakers:
Formulation

All Speakers

Full
Programme:
Day One

Full Programme: Day Two

Venue Information

Book Now

Day Two | October 3 2025

Keynote Address Conference Room 4 Coral 4



KEYNOTE ADDRESS IN CORAL 5: How 'Proximity Medicines' Are Transforming Pharmacotherapy

Multispecific medicines - both large and small molecule - are on the ascendancy. Half of the 72 FDA-approved multispecific drugs have gained approval since 2020, and from 2022-24, multispecifics accounted for 1/6th of FDA approvals. Among the different categories of multispecific drugs, proximity medicines are of particular interest. These medicines typically work by either localizing the therapeutic molecule or recruiting a regulatory mechanism in the body to modulate the target. I will discuss the advantages conferred by multispecificity with particular emphasis on proximity medicines, and will describe a category of proximity medicines – LOCKTACs – that work by stabilizing a pre-existing complex.

RAY DESHAIES, Former Senior Vice President of Global Research,

Amgen

Q&A session & transition time between conference rooms **AUTOMATION &** DRUG DISCOVERY PROGRAM **FORMULATION & DELIVERY PROGRAM ROBOTICS PROGRAM IMPLEMENTING LAB AUTOMATION &** LARGE MOLECULE FORMULATION DMPK, PHARMACOLOGY & SAFETY **SMALL MOLECULE DELIVERY DIGITIZATION CONFERENCE ROOM 1 CORAL 1 CONFERENCE ROOM 2 CORAL 2** CONFERENCE ROOM 6 SEAGLASS **CONFERENCE ROOM 3 CORAL 3** Morning Track Chair: SHUANGWEI LI, Director Morning Track Chair: FABIEN VINCENT, Morning Track Chair: SEVERIN SCHNEEBELI, Morning Track Chair: VIVEK GUPTA, Associate of Toxicology, Calibr-Skaggs Institute for Consultant, Former Pharmacology Lab Head, Associate Professor, Purdue University Professor, St. John's University Innovative Medicines Pfizer Platinum/Gold Solution Provider **Solution Provider Presentation Improving Drug Metabolism Outcomes** INTERACTIVE With Mechanistic In Silico Modelling Presentation To avoid late-stage failure of drug candidates, understanding compound metabolism is crucial. Here, we demonstrate how mechanistic in silico SPONSORED WORKSHOP: Tackling CMC & Manufacturing Challenges modelling provides an early opportunity to spot Of Complex LNP-Based Biopharmaceuticals metabolic liabilities and resolve them by guiding the design of improved compounds. For Oncological, Gene Editing & Vaccine **Applications** For sponsorship opportunities please contact sponsorship@oxfordglobal.com optibrium SARTURIUS MATTHEW SEGALL, Chief Executive Officer, Senior Representative, **Optibrium** Sever Pharma Solutions Q&A session & transition time between conference rooms Q&A session & transition time between conference rooms **How Close Are We? The Evolving Science Automated, Integrated Wet Lab & Digital Formulation Considerations For Polymeric Of Human PK Prediction Platform Implants** This talk will explore the current landscape of human pharmacokinetic (PK) prediction, focusing on our ability to estimate clearance, volume of This talk outlines Boehringer Ingelheim's strategic initiatives in digital and lab automation in the large molecule research space. It highlights investments •Formulation development is guided through evaluating API and polymer properties, stability, manufacturability, compatibility with the device in automation systems, digital integration, and distribution, and oral bioavailability. We'll also delivery system, and non-clinical studies examine a case study addressing non-linearity lab orchestration to enhance biotherapeutics • Release of implants depend on polymer in PK and its impact on first-in-human dose selection—highlighting practical strategies, limitations, and evolving methodologies in human research, improve efficiency, and drive innovation properties, drug substance properties, and the at the Biotherapeutics department. process parameters PK predictions. KAUSHEEK NANDY, Digital Transformation KISHORE PASIKANTI, Senior Director, DMPK, Director - Research, ELENA LIANG, Principal Research Scientist, Grünenthal **Boehringer Ingelheim AbbVie** Q&A session & transition time between conference rooms Q&A session & transition time between conference rooms

BROCHURE CONTENTS

Welcome

Benefits of **Attending**

Sponsors

Special Event Features

Agenda at a Glance

Featured Speakers: Discovery

Featured Speakers: Formulation

All Speakers

Full **Programme:** Day One

Full **Programme:** Day Two

Venue Information

Book Now

We pioneered a sphingomyelin-conjugated nanovesicle platform (Camptothesome) to safely deliver camptothecin, achieving synergistic immunochemotherapy in colorectal cancer (Nature Nanotechnology, 2021). This strategy was extended to IDO1 inhibitor, Epacadostat for improved melanoma immunotherapy (Nature) improved melanoma immunotherapy (Nature Communications, 2023). More recently, we developed Paclitaxome, a sphingolipid-derived paclitaxel nanovesicle, enhancing combination therapies in triple-negative breast and pancreatic cancers (Nature Cancer, 2025). Additionally, we engineered cholesterol-modified sphingomyelin bilayers for efficient delivery of small molecules and siRNA (Nature Communications, 2024). Collectively, these advances establish sphingolipid nanotherapeutics as next-generation cancer treatments.

JIANQIN LU, John A. & Frances P. Ware Endowed Associate Professor, University of Arizona & Co-Founder, **SPH Therapeutics**

- •Strategies for data management in labs of the
- Considerations & challenges

Moderator: YUE WEBSTER, Vice President, Model Driven Drug Discovery Platforms, Eli Lilly

ROUNDTABLE DISCUSSION 2:

From Drug Product Development To **Overcoming Regulatory Hurdles** Regulatory lifecycle

 Aligning product development strategies with regulatory expectations

Moderator: SHILPA THOSAR, Former Executive Director, Cara Therapeutics

- technology FluidCrystal®
- Small volume, ready-to-use formulations for improved compliance and better efficacy

MARIA WINZELL, Senior Director Drug

- Examples of a variety of peptide formulations with extended half-lives with clinical data
- •The transition to low global warming potential propellants in metered dose inhalers is essential for reducing the environmental impact of pharmaceutical aerosols
 - This presentation provides a technical overview of the challenges and strategies to address the change and significantly reducing the carbon foot print of MDIs

ENRICO ZAMBELLI, Sustainable Formulation Project Unit Manager, Chiesi

BROCHURE CONTENTS

Welcome

Benefits of **Attending**

Sponsors

Special Event **Features**

Agenda at a Glance

Featured Speakers: Discovery

Featured Speakers: Formulation

All Speakers

Full **Programme:** Day One

Full Programme: Day Two

Venue Information

Book Now

Linked in X @OGConferences

Q&A session & transition time between conference rooms

Development,

Camurus

		tober 3 2025			
	DRUG DISCOVERY PROGRAM		FORMULATION & DELIVERY PROGRAM		
	DMPK, PHARMACOLOGY & SAFETY	IMPLEMENTING LAB AUTOMATION & DIGITIZATION	LARGE MOLECULE FORMULATION	SMALL MOLECULE DELIVERY	
	CONFERENCE ROOM 1 CORAL 1	CONFERENCE ROOM 2 CORAL 2	CONFERENCE ROOM 6 SEAGLASS	CONFERENCE ROOM 3 CORAL 3	
	Bronze Solution Provider Presentation	Bronze Solution Provider Presentation	Bronze Solution Provider Presentation	Solution Provider Presentation	
12:40	For sponsorship opportunities please contact sponsorship@oxfordglobal.com	For sponsorship opportunities please contact sponsorship@oxfordglobal.com	For sponsorship opportunities please contact sponsorship@oxfordglobal.com	ARDENA	
				Senior Representative, Ardena Bioanalysis	
13:05		V LUNCH	BREAK 👺		
- 14:05					
	DMPK, PHARMACOLOGY & SAFETY	DEGRADERS & MOLECULAR GLUES	LARGE MOLECULE FORMULATION	LARGE MOLECULE & RNA DELIVERY	
	CONFERENCE ROOM 1 CORAL 1	CONFERENCE ROOM 2 CORAL 2	CONFERENCE ROOM 6 SEAGLASS	CONFERENCE ROOM 3 CORAL 3	
	Afternoon Track Chair: SHUANGWEI LI, Director of Toxicology, Calibr- Skaggs Institute for Innovative Medicines	Afternoon Track Chair: DAVID BUCKLER, Executive Director, Program Management, Regeneron	Afternoon Track Chair: SEVERIN SCHNEEBELI, Associate Professor, Purdue University	Afternoon Track Chair: MARK ECCLESTON, Chief Executive Officer, ValiRx	
	Toxicology In Small Molecule Drug Discovery: From Target Safety Assessment To IND	RapaGlue™: A Novel Non-Degrading Molecular Glue Modality For Unlocking The Hard To Drug Proteome	Solving Key Function & Formulation Challenges To Enable Development Of A Novel First In Class Thioredoxin-Based Therapeutic	PANEL DISCUSSION: Sustainability Impact Of Different Drug Delivery Methods	
14:05	Overview of the critical role toxicology plays in small molecule drug discovery, from early target safety assessment through IND-enabling studies Key strategies for identifying, characterizing, and mitigating safety risks during candidate selection and lead optimization Practical guidance on designing and timing toxicology studies to align with regulatory expectations and support successful IND submissions.	Rapafuysn's platform of non-degrading molecular glues is uniquely positioned to target intracellular proteins and the cytosolic side of transmembrane proteins unlocking the hard to drug proteome. The company's platform of RapaGlue's takes advantage of the cytosolic residing FKBP12 to form ternary complexes with disease target proteins. The presentation will describe successful hit campaign highlighting our progress in inhibiting the GTPase, GSTP1 a target for ferroptosis.	 Thioredoxin is a previously unexploited secreted stress-protectant protein family with anti-inflammatory, anti-oxidative & ferroptosis-inhibiting activity Thioredoxin protects both normal & cancer cells & has demonstrated poor pharmacology with rapid clearance & an association with chemoresistance during cancer treatment Thioredoxin ORP100S has been designed & formulated to greatly improve pharmacokinetics & increase potency, with no evidence of protective function in multiple cancer cell lines 	Inhalation Oral delivery Injection	
	SHUANGWEI LI, Director of Toxicology, Calibr-Skaggs Institute for Innovative Medicines	RICK EWING, Vice President, Head of Chemistry, Rapafusyn Pharmaceuticals	PETER HEIFETZ, Chief Executive Officer, Orpro Therapeutics		
	Q&A session & transition time between conference rooms				

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Special Event Features

Agenda at a Glance

Featured
Speakers:
Discovery

Featured
Speakers:
Formulation

All Speakers

Full
Programme:
Day One

Full Programme: Day Two

Venue Information

Book Now

Day Two October 3 2025				
DRUG DISCOVERY PROGRAM		FORMULATION & DELIVERY PROGRAM		
SCREENING & HIT IDENTIFICATION CONFERENCE ROOM 1 CORAL 1	DEGRADERS & MOLECULAR GLUES CONFERENCE ROOM 2 CORAL 2	LARGE MOLECULE FORMULATION CONFERENCE ROOM 6 SEAGLASS	LARGE MOLECULE & RNA DELIVERY CONFERENCE ROOM 3 CORAL 3	
PANEL DISCUSSION: Successful Human Dose Prediction Across Modalities - Considerations & Challenges Optimization of small molecule compounds Traditional vs novel modalities Ensuring quality PK predictions Moderator: SHUANGWEI LI, Director of Toxicology, Calibr-Skaggs Institute for Innovative Medicines Panellists:	Discovery And Characterization Of A Clinical-Stage Molecular Glue Degrader Of WEE1 Kinase, BMS-986463, For The Treatment Of Advanced Solid Tumors WEE1 is an essential cell cycle regulator kinase that prevents mitotic division of cells with DNA damage. Some tumors disproportionally depend upon WEE1 for survival and WEE1-selective inhibitors have shown clinical promise. We describe the discovery and pharmacological characterization of BMS-986463, a first-in-class molecular glue degrader of WEE1 currently in Phase I enrolling patients in multiple oncology indications.	Spirulina As A Next-Generation Biomanufacturing Platform: Low Cost Biologics At Scale Lumen Bioscience has engineered spirulina into a platform for producing oral and intranasal biologic drugs. This talk will highlight the platform's molecular tools, manufacturing capabilities, and therapeutic applications, with examples spanning from C. difficile infection to metabolic disease.	PANEL DISCUSSION CONTINUED: Sustainability Impact Of Different Drug Delivery Methods Moderator: NAOMI O'GRADY, Vice President of Product Marketing, Quantum Si Panellists: ENRICO ZAMBELLI, Sustainable Formulation Project Unit Manager, Chiesi JACK ROGERS, Director of Neurochemistry, Harvard University	
KISHORE PASIKANTI, Senior Director, DMPK, Grünenthal SHINJI YAMAZAKI, Senior Director of PBPK Consultancy, Certara	JOSH BAUGHMAN, Scientific Director, Bristol Myers Squibb	CRAIG BEHNKE, Executive Vice President, Production & Development, Lumen Bioscience	CATHERINE CAHILL, Assistant Professor, Harvard Medical School VIVEK GUPTA, Associate Professor, St. John's University	

14:30

Q&A session & transition time between conference rooms

Small Molecule Discovery: Unfolding Precision Medicines Using Phenotypic Screening In Primary Human Cells	Novel Ultra High Density Screening For Molecular Glues	PANEL DISCUSSION: Optimizing Formulation Of High Dosage Biologics	Toward Delivery Of Improved Efficacy, Greater Safety, & Enhanced Patient Experience During & After Treatment
 Rationale for the use of phenotypic screening Considerations for establishing a high quality phenotypic screen Hit identification and de-convolution in human disease models 	 Identification of novel E3 ligases to expand the toolbox for TPD drug discovery Prospective design of monovalent direct degraders Discovery of selective monovalent direct degraders of SMARCA2 	 Viscosity, aggregation, and stability issues Strategies for formulation optimization Scale-up and regulatory alignment 	 Erkki Ruoslahti's "cellular zipcodes" and a novel delivery mechanism of action Improved efficacy: how? Greater safety: how? Enhanced patient experience: how? Challenges to preclinical development of productions. Future vision
5			
		Moderator: RAMESH KASHI, Former Senior Scientific Director, Bristol Myers Squibb	
		Panellists:	
BETH HOFFMAN, President & Chief Executive	PEGGY THOMPSON, Vice President, Head of	SUNITA YADAV, Associate Director, Novartis	
Officer, Origami Therapeutics, Inc.	Biology, Plexium	CRAIG BEHNKE, Executive Vice President, Production & Development, Lumen Bioscience	DAVID LOYND, Chief Executive Officer, EnduRx
	Q&A session & transition tim	e between conference rooms	

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Special Event Features

Agenda at a Glance

Featured
Speakers:
Discovery

Featured
Speakers:
Formulation

All Speakers

Full
Programme:
Day One

Full Programme: Day Two

Venue Information

Book Now

	Day Two October 3 2025			
	DRUG DISCOVERY PROGRAM		FORMULATION & DELIVERY PROGRAM	
	SCREENING & HIT IDENTIFICATION	DEGRADERS & MOLECULAR GLUES	LARGE MOLECULE FORMULATION	LARGE MOLECULE & RNA DELIVERY
	CONFERENCE ROOM 1 CORAL 1	CONFERENCE ROOM 2 CORAL 2	CONFERENCE ROOM 6 SEAGLASS	CONFERENCE ROOM 3 CORAL 3
	VS@Lilly: Enablement Of A Dedicated Platform For Identifying Novel Small-Molecule Binders	Modeling Of Degrader's Oral Bioavailability & In Vivo PK Properties	Formulating Proteins For Maximum Stability	Beyond Intrathecal: Less-Invasive Oligonucleotide Deliverey Across The Blood Brain Barrier
5:20	The VS@Lilly project represents a significant advancement in computational chemistry, focusing on the development of a dedicated platform for identifying novel small-molecule binders. This platform supports routine ultralarge-scale virtual screening, leveraging advanced technology to explore commercially available chemical spaces and identify primary or backup chemical starting points. It features an extensive database with over 40 million off-the-shelf compounds and several billion compounds available through on-demand synthesis, all in various formats for efficient screening.	 Oral bioavailability of TPDs, especially larger sized bifunctional molecules (i.e. PROTAC), is one of the most challenging properties to be optimized for oral drug discovery A comprehensive in vivo data set were collected from public domain and 2D/3D descriptors were developed to establish models for oral bioavailability We address the different behavior of models by using data sets from different type of animal models Going beyond ML models, mechanistic based method was established to infer in vivo PK parameters 	 Solid-state characterization of mRNA LNPs to identify formulation and lyophilization conditions to ensure long-term stability Predicting protein stability, including mAbs, in the solid state – formulation approaches to ensure long-term stability New technologies for in situ and non-destructive characterization of aseptic solid formulations 	 Trans-nasal route for delivering BBB-impermeant - targeting the olfactory epithelium BDNF antagoNAT (Oligonucleotide) delivery to brain - kinetics Efficacy in a neurodegenerative model
	SHANTHI NAGARAJAN, Director, Lilly Small Molecule Discovery Eli Lilly	LEI JIA, Associate Director, Drug Discovery Data Science, Johnson & Johnson	ERIC MUNSON, Professor, Purdue University	ANISHA DSOUZA, Research Fellow, Massachusetts Eye and Ear Infirmary, Harvard Medical School
		Q&A session & transition tim	e between conference rooms	
	Donor to Donor Variability in Pharmacology: Mole Hill Or Mountain?	Preclinical Evaluation Of BMS-986365: A First-In-Class Dual AR Ligand-Directed Degrader And Antagonist For mCRPC Therapy		
5:45	 Major transition towards using primary cell assays in support of drug discovery programs for autoimmune diseases to improve translation An analysis of >25 primary cell assays used for HTS and SAR will be presented, including an answer to the question of donor to donor variability Specific lessons and strategies learned to facilitate the use of these physiologically relevant assays will be shared 	 BMS-986365 is a heterobifunctional AR degrader and antagonist for wildtype and mutant AR Inhibits AR target gene transcription and cell proliferation more effectively than enzalutamide Maintains low AR protein despite elevated transcript levels Shows robust efficacy in cell line and patient-derived xenograft models Clinically lowers PSA in mCRPC post-ARPI, effective in resistant disease 	Attendees are welcome to join co-located sessions	Attendees are welcome to join co-located sessions
	FABIEN VINCENT, Consultant, Former Pharmacology Lab Head, Pfizer	SURENDRA NAYAK, Scientific Associate Director, Bristol Myers Squibb		

F END OF CONFERENCE

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Special Event Features

Agenda at a Glance

Featured
Speakers:
Discovery

Featured
Speakers:
Formulation

All Speakers

Full
Programme:
Day One

Full Programme: Day Two

Venue Information

Book Now

Linked in

© OGConferences

16:10

.

Soak in Stunning Waterfront Views at **Sheraton San Diego Resort**

Sheraton San Diego Resort dazzles guests with spectacular views of the marina or downtown skyline. Experience San Diego with a central location in the heart of the harbor, yet just minutes from San Diego Airport with a free shuttle.

Enjoy being near downtown, Gaslamp Quarter, San Diego Zoo, and Petco Park, for a fun time in the city. Our newly renovated marina tower shines with coastal hues and modern amenities and our light-filled accommodations have a private balcony with seating. Enjoy picturesque views of the bay or marina in the classic bay tower guest rooms that also boast private balconies with seating. Stop by BreweryX for a refreshing brew or discover authentic Baja dishes at Rumorosa. Enjoy our sprawling outdoor pool complex, with ample opportunities to soak in the San Diego sun or lounge in poolside cabanas, cocktail in hand. Featuring over 130,000 sq ft of venue space accentuated by waterfront views, our San Diego Harbor Hotel is an inspired choice for weddings and meetings.

DIRECTIONS BY AIR

From San Diego International Airport (SAN), the hotel is just 1.5 miles from the airport.

Shuttle: Use the free Sheraton shuttle, available at Terminal 1 & Terminal 2. Look for the "Hotel Courtesy Shuttle" sign. If Shuttle is unavailable: Take the 992 bus from the airport to the Harbor Island Drive & Sheraton Way stop (5-minute ride). Walk 5 minutes to the hotel.

DIRECTIONS BY TRAM/BUS

The total journey from downtown via tram and bus should take around 20-30 minutes.

- Take the San Diego Trolley:
- Use the Green Line or another line that connects to the Santa Fe Depot station.
- Transfer to Bus or Walk:
- From Santa Fe Depot, take Bus 992 (Airport Route) toward the San Diego International Airport. Exit at the hotel stop near Harbor Island.
- Alternatively, walk approximately 30 minutes (1.5 miles) along Harbor Drive to the hotel.



Sheraton San Diego Resort

1380 Harbor Island Drive, San Diego, CA



BROCHURE CONTENTS

Welcome

Benefits of **Attending**

Sponsors

Special Event Features

Agenda at a Glance

Featured Speakers: Discovery

Featured Speakers: Formulation

All Speakers

Full **Programme:** Day One

Full **Programme:** Day Two

Venue Information

Book Now

Linkedin

X @OGConferences